GlassScriptPhysician profile
Grace Y Mullins
NPI 1932136264
$4,318.08
in general payments reported to CMS, 2019-2025
39 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,136 · 2022: $726 · 2023: $1,215 · 2024: $744 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $689.15 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $647.22 | 2021-2025 | |
| Medtronic, INC. | $489.64 | 2023-2025 | Intellis Adaptivestim, Accurian, Synchromedii |
| Collegium Pharmaceutical, INC. | $448.43 | 2021-2024 | Xtampza, Belbuca |
| Lilly USA, LLC | $253.59 | 2021-2024 | Emgality, Reyvow |
| Protega Pharmaceutials INC | $228.52 | 2022-2023 | Roxybond |
| Nevro Corp. | $136.56 | 2021-2024 | Senza |
| Merz North America, INC. | $108.23 | 2021 | |
| Amgen INC. | $97.63 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $92.18 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $91.60 | 2021 | |
| Ibsa Pharma INC. | $79.10 | 2022-2023 | Tirosint, Licart |
| Almatica Pharma LLC | $74.01 | 2023 | Gralise |
| Pfizer INC. | $71.76 | 2023-2025 | |
| Si-Bone, INC. | $62.17 | 2021-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.